The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.

MLA

Griffiths, C. E. M., et al. “The EGALITY Study: A Confirmatory, Randomized, Double-Blind Study Comparing the Efficacy, Safety and Immunogenicity of GP2015, a Proposed Etanercept Biosimilar, vs. the Originator Product in Patients with Moderate-to-Severe Chronic Plaque-Type Psoriasis.” The British Journal of Dermatology, vol. 176, no. 4, Apr. 2017, pp. 928–38. EBSCOhost, https://doi.org/10.1111/bjd.15152.

APA

Griffiths, C. E. M., Thaçi, D., Gerdes, S., Arenberger, P., Pulka, G., Kingo, K., Weglowska, J., Hattebuhr, N., Poetzl, J., Woehling, H., Wuerth, G., & Afonso, M. (2017). The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. The British Journal of Dermatology, 176(4), 928–938. https://doi.org/10.1111/bjd.15152

Chicago

Griffiths, C E M, D Thaçi, S Gerdes, P Arenberger, G Pulka, K Kingo, J Weglowska, et al. 2017. “The EGALITY Study: A Confirmatory, Randomized, Double-Blind Study Comparing the Efficacy, Safety and Immunogenicity of GP2015, a Proposed Etanercept Biosimilar, vs. the Originator Product in Patients with Moderate-to-Severe Chronic Plaque-Type Psoriasis.” The British Journal of Dermatology 176 (4): 928–38. doi:10.1111/bjd.15152.